Rapport Therapeutics (RAPP) Accumulated Expenses (2024 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Accumulated Expenses of $8.7 million for Q1 2026, up 315.68% year-over-year from $2.1 million in Q1 2025, and up 22.49% quarter-over-quarter from $7.1 million in Q4 2025.
Rapport Therapeutics (RAPP) Accumulated Expenses (2024 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Accumulated Expenses for 3 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 315.68% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (up 315.68% YoY), while the FY2025 annual figure was $7.1 million, up 92.02% from the prior year.
- Accumulated Expenses improved to $8.7 million in Q1 2026 per RAPP's latest filing, from $7.1 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $8.7 million in Q1 2026 and bottomed at $1.8 million in Q2 2024.
- Historically, Accumulated Expenses has averaged $4.5 million across 3 years, with a median of $3.7 million in 2024.
- Annual changes were most pronounced in 2025 — Accumulated Expenses soared 64.67% — and 2026, when it soared 315.68%.
- Rapport Therapeutics' Accumulated Expenses stood at $3.7 million in 2024, then surged by 92.02% to $7.1 million in 2025, then advanced by 22.49% to $8.7 million in 2026.
- Business Quant data shows RAPP's Accumulated Expenses at $8.7 million in Q1 2026, $7.1 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.16 Mn |
| Mar 31, 2026 | 8.72 Mn |
| Dec 31, 2025 | 7.12 Mn |
| Sep 30, 2025 | 5.04 Mn |
| Jun 30, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 3.71 Mn |
| Jun 30, 2024 | 1.81 Mn |